(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 April 2013 (18.04.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/055874 A3

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/32* (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:
PCT/US2012/059683

(22) International Filing Date:
11 October 2012 (11.10.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/547,535	14 October 2011 (14.10.2011)	US
61/567,015	5 December 2011 (05.12.2011)	US
61/657,669	8 June 2012 (08.06.2012)	US
61/682,037	10 August 2012 (10.08.2012)	US
61/694,584	29 August 2012 (29.08.2012)	US

(71) Applicants: **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, California 94080 (US). **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH). **ROCHE PRODUCTS LIMITED** [GB/GB]; 6 Falcon Way, Shire Park Hexagon Place, Welwyn Garden City Hertfordshire AL7 1TW (GB).

(72) Inventors; and

(71) Applicants : **ALAVATTAM, Sreedhara** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **AMLER, Lukas C.** [DE/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **BENYUNES, Mark C.** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **CLARK, Emma L.** [GB/GB]; c/o Roche Products Limited, 6 Falcon Way, Shire Park Hexagon Place, Welwyn Garden City Hertfordshire AL7 1TW (GB). **DE TOLEDO PELIZON, Christina H.** [BR/CA]; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel (CH). **KWONG GLOVER, Zephania W.** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **MITCHELL, Lada** [GB/CH]; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel (CH). **RATNAYAKE, Jayantha** [GB/GB]; c/o Roche Products Limited, 6 Falcon Way, Shire Park Hexagon Place, Welwyn Garden City Hertfordshire AL7 1TW (GB). **ROSS, Graham A.** [GB/GB]; c/o Roche Products Limited, 6 Falcon Way, Shire Park Hexagon Place, Welwyn Garden City Hertfordshire AL7 1TW (GB). **WALKER, Ru-Amir** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US).

(74) Agents: **LEE, Wendy M.** et al.; Genentech, Inc., 1 DNA Way, MS 49, South San Francisco, California 94080 (US).

[Continued on next page]

(54) Title: USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB




FIG. 8

(57) Abstract: The present application describes uses for and articles of manufacture including Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity; treating early-stage HER2-positive breast cancer; treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag; treating HER2-positive metastatic gastric cancer; treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and Vinorelbine; treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and aromatase inhibitor; and treating low HER3 ovarian, primary peritoneal, or fallopian tube cancer. It also describes an article of manufacture comprising a vial with Pertuzumab therein and a package insert providing safety and/or efficacy data thereon; a method of making the article of manufacture; and a method of ensuring safe and effective use of Pertuzumab related thereto. In addition the application describes an intravenous (IV) bag containing a stable mixture of Pertuzumab and Trastuzumab suitable for administration to a cancer patient.

WO 2013/055874 A3

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report**:
20 June 2013